ascrinvacumab
mAbexperimental
Ascrinvacumab (PF-03446962) is a monoclonal antibody designed for the treatment of cancer. It is an ALK1 inhibitor. — Wikipedia
Clinical trial activity
7 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2007 (NCT00557856)
Timeline
Indications
Mechanism of action
ACVRL1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAscrinvacumab ↗
- ChEMBLCHEMBL2109295 ↗
Also known as
- ascrinvacumab
- ascrinvacumab
- pf03446962
- pf-03446962
- pf-03446962
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03893695 | Phase 1/Phase 2 (Phase 2) | Apr 25, 2019 | Suzhou Kintor Pharmaceutical Inc, |
| NCT02116894 | Phase 1 | Aug 1, 2014 | Duke University, Pfizer |
| NCT01911273 | Phase 2 | Oct 1, 2013 | Pfizer |
| NCT01620970 | Phase 2 | Jul 1, 2012 | University of Milan |
| NCT01486368 | Phase 2 | Nov 1, 2011 | Canadian Cancer Trials Group, University of Alberta, University of Ottawa |
| NCT01337050 | Phase 1 | Jul 1, 2011 | Pfizer |
| NCT00557856 | Phase 1 | Nov 1, 2007 | Pfizer |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 4 | 3 | 2 | 2007 |
| Canadian Cancer Trials Group | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Suzhou Kintor Pharmaceutical Inc, | For profit | 1 | 1 | 1 | 2019 |
| University of Alberta | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of Milan | Academic/Hospital | 1 | 1 | 1 | 2012 |
| University of Ottawa | Academic/Hospital | 1 | 0 | 1 | 2011 |
7 organizations
Page 1 / 1